1. Early and Intensive T2D Management:

3. Program Goals

6. TECOS Sitagliptin in Patients With T2D and Established CVD

7. FDA Drug Safety Communication

8. Guidelines: Initial Combination Therapy Recommendations

9. Fixed-Dose Combination Therapy Rationale for Use

11. Dapagliflozin/Saxagliptin Add-On to MET

12. Combination Therapy With DPP-4 Inhibitors: Meta-Analysis

13. Combination Therapy With SGLT2 Inhibitors Add-On to MET -- Meta-Analysis

14. SGLT2 Inhibitor + GLP-1 Receptor Agonist Combo Ongoing Trials

15. Initial Combination Therapy: CANA + MET XR in Drug-Naïve Patients Study Design

16. Initial Combination Therapy: CANA + MET XR in Drug-Naïve Patients Mean Change in HbA1c

17. Initial Combination Therapy: CANA + MET XR in Drug-Naïve Patients Proportion of Patients With HbA1c < 7.0%

18. Triple Therapy: DAPA Add-on to SAXA Plus MET Study Design

19. Triple Therapy: DAPA Add-on to SAXA + MET Distribution of HbA1c in Patients at Week 2

20. Fixed-Dose Combination Potential Benefits

21. Abbreviations

22. Abbreviations (cont)

23. References

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)